Who is sponsoring TACE-EBRT?

TACE-EBRT is sponsored by Shanghai Zhongshan Hospital.

What condition does TACE-EBRT study?

TACE-EBRT studies Hepatocellular Carcinoma.

What drugs are being tested in TACE-EBRT?

Interventions: Transcatheter arterial chemoembolization, External- beam radiotherapy.

What is the status of TACE-EBRT?

TACE-EBRT is currently UNKNOWN.

Last reviewed 2020-04-10 · How we verify

A Study of Comparison of TACE Combination With and Without EBRT for Advanced HCC (TACE-EBRT)

NCT03116984 PHASE3 UNKNOWN

This clinical trial is a prospective, randomized, controlled and multicenter study.And the trial is going to better control intrahepatic tumors for hepatocellular carcinoma(HCC) patients who meet the inclusion criterion.The patients were divided into two groups, the group A by TACE and the other group B by external- beam radiotherapy(EBRT) after 2 times TACE. Then the therapeutic effects and toxicities of TACE and EBRT are evaluated during the follow-up period. The study design plans to enroll 300 patients, and each group includes 150 cases.

Details

Lead sponsor	Shanghai Zhongshan Hospital
Phase	PHASE3
Status	UNKNOWN
Enrolment	300
Start date	Sun Jan 01 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Thu Dec 31 2020 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Hepatocellular Carcinoma

Interventions

Transcatheter arterial chemoembolization
External- beam radiotherapy

Countries

China